Product Information
MESALAMINE DR 1.2 GM TABLET is a generic product labeled by Takeda Pharmaceuticals America, Inc., priced at $0.7953 per EA under NDC 54092010001. Its NADAC has been published 462 times since Oct 18, 2017.
FDA first approved this application on Jan 16, 2007. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
The High Outlier badge above means this manufacturer's average price in the MESALAMINE market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
1.2 g/1
Manufacturer
Takeda Pharmaceuticals America, Inc.NDC
54092010001
Classification
Generic
Dosage Form
TABLET, DELAYED RELEASE
Route
ORAL
Effective Date
8/19/2026
Active Ingredients
MESALAMINEApproval Type
Authorized Generic (NDA)
FDA Application
NDA022000FDA Approved
1/16/2007
TE Code
AB
On Market Since
8/29/2017
Pharmacological Classes
Price Statistics
The NADAC for MESALAMINE DR 1.2 GM TABLET has been published 462 times since Oct 18, 2017, and over the history we have for it it has declined 89.0%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.7953 per EA |
|---|---|
| All-time high | $7.2063 (Nov 15, 2017) |
| All-time low | $0.7953 (Aug 19, 2026) |
| 52-week high | $1.0132 |
| 52-week low | $0.7953 |
| Median price | $2.7476 |
| Average price | $2.9414 |
| Largest weekly change | +45.9% (Aug 21, 2024) |
| Weeks tracked | 462 |
| Tracking since | Oct 18, 2017 |
1W
N/A
1M
N/A
3M
-2.3%
6M
-10.7%
1Y
-21.5%
3Y
-64.1%
5Y
-73.3%
All
-89.0%
Last surveyed Aug 19, 2026 — this NDC no longer appears in the current weekly NADAC file.
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the MESALAMINE market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Takeda Pharmaceuticals America, Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
MESALAMINE market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Aminosalicylate class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of MESALAMINE DR 1.2 GM TABLET?
The current National Average Drug Acquisition Cost (NADAC) for MESALAMINE DR 1.2 GM TABLET, manufactured by Takeda Pharmaceuticals America, Inc., is $0.7953 per EA (NDC 54092010001), effective Aug 19, 2026.
How has the price of MESALAMINE DR 1.2 GM TABLET changed over time?
Over the history we have for it, the NADAC for MESALAMINE DR 1.2 GM TABLET has declined 89.0%. It has been tracked across 462 weekly CMS publications since Oct 18, 2017.
What are the highest and lowest recorded NADAC prices for MESALAMINE DR 1.2 GM TABLET?
Since Oct 18, 2017, the NADAC for MESALAMINE DR 1.2 GM TABLET has ranged from a low of $0.7953 (Aug 19, 2026) to a high of $7.2063 (Nov 15, 2017), with a median of $2.7476 per EA.
Are there cheaper alternatives to MESALAMINE DR 1.2 GM TABLET?
No other NADAC-published product currently shares the active ingredient and strength of MESALAMINE DR 1.2 GM TABLET in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures MESALAMINE DR 1.2 GM TABLET?
MESALAMINE DR 1.2 GM TABLET (NDC 54092010001) is labeled by Takeda Pharmaceuticals America, Inc., and CMS classifies it as a generic product.